Guillain-Barré syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barré syndrome.

Ling, Ling; Bagshaw, Sean M.; Villeneuve, Pierre-Marc

More cases of GBS have been reported after SARS-CoV-2 infection than after vaccination; the benefits of SARS-CoV-2 vaccination outweigh the potential adverse effects for nearly all patients. The patient had received his childhood vaccinations without adverse effects, but this had been his first vaccination against influenza and he did not have any further vaccinations until the SARS-CoV-2 pandemic. The patient had a history of hypertension, dyslipidemia, insulin-dependent diabetes mellitus, nephrolithiasis, obesity, anxiety and Guillain-Barré syndrome (GBS) after vaccination against influenza. Guillain-Barré syndrome (GBS) has very rarely been described after vaccination, but a causal relationship has not been established.

INFLUENZA; GUILLAIN-Barre syndrome; SARS-CoV-2; VACCINE safety; VACCINATION; CHRONIC inflammatory demyelinating polyradiculoneuropathy

Canadian Medical Association Journal (CMAJ), 2021, Vol 193, Issue 46, pE1766

0820-3946

Academic Journal

10.1503/cmaj.210947